Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 147Leukemia, Lymphocytic, Chronic, B-Cell 140Lymphoma 116Lymphoma, Non-Hodgkin 112Leukemia, Myeloid, Acute 95Leukemia 92Myelodysplastic Syndromes 90Hodgkin Disease 68Lymphoma, B-Cell 61Leukemia, Myelogenous, Chronic, BCR-ABL Positive 53Multiple Myeloma 52Lymphoma, Mantle-Cell 52Lymphoma, Large B-Cell, Diffuse 50Lymphoma, Follicular 50Recurrence 43Burkitt Lymphoma 41Hematologic Neoplasms 36Myeloproliferative Disorders 31Lymphoma, B-Cell, Marginal Zone 30Neoplasms, Plasma Cell 20Primary Myelofibrosis 19Leukemia, Biphenotypic, Acute 18Anemia, Refractory, with Excess of Blasts 18Lymphoma, T-Cell 17Leukemia, Myelomonocytic, Chronic 15Graft vs Host Disease 15Anemia, Aplastic 15Leukemia, Prolymphocytic 14Neoplasms 12Leukemia, B-Cell 12

Interventions

Temozolomide 9Filgrastim 7Specimen Handling 6X-Rays 5Rituximab 5Radiotherapy 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Psychiatric Rehabilitation 4Nuclear Medicine Department, Hospital 4Methotrexate 4Etoposide 4Cyclophosphamide 4Biopsy 4etoposide phosphate 3Pemetrexed 3Melphalan 3Cytarabine 3Carboplatin 3tazemetostat 2sargramostim 2olaparib 2larotrectinib 2erdafitinib 2ensartinib 2Vincristine 2Vemurafenib 2Topotecan 2Thiotepa 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × fludarabine × Lymphoid × Clear all
NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Miltenyi Biomedicine GmbH

Phase 2 Recruiting
248 enrolled
CNSLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡